Loading
A phase 2 trial of Transcranial focused ultrasound systems in Glioma & glioblastoma, run by Northwestern University, now recruiting.
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma is a phase 2 interventional study registered as NCT05864534 by Northwestern University, with 25 participants planned, started 2024-01-19 and due to reach its primary completion in 2031-07-31. Interventions recorded: Balstilimab, Botensilimab, Liposomal Doxorubicin, Sonocloud-9 (SC-9). Conditions recorded: Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme.
Linked to the technology Transcranial focused ultrasound systems because the registry names it ("sonocloud") among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
Shares Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud), Glioma & glioblastoma and the tag pipeline.
Shares Balstilimab and the tag pipeline.
Shares Doxorubicin, Glioma & glioblastoma and the tag pipeline.
Shares Doxorubicin, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.